Recent News

Prognostic Value of Residual Lymphadenopathy After Chemoimmunotherapy for CLL

Weight Gain With Ibrutinib Treatment in Patients With CLL

Aging and Stereotypic B-Cell Receptors Associated With CLL

Using Minimal Residual Disease Detection to Monitor Outcomes in CLL Treatment

First-in-Human Study of CD200 Blockade With Samalizumab in CLL

Update on Resistance to Targeted Therapies in CLL

STIM1 Targeting as a Novel Therapy for Patients With CLL

SOHO 2019: Novel Reversible BTK Inhibitor Therapy for Chronic Lymphocytic Leukemia

SOHO 2019: ‘More Questions Than Answers’ in CLL Therapy

Case of Cranial Aspergillosis in a Patient Receiving Ibrutinib for CLL

Extended Ibrutinib Treatment in RESONATE CLL Trial

ALPINE Trial: Bruton’s Tyrosine Kinase Inhibitor in Resistant CLL

Managing Toxicity With Duvelisib in CLL: Dose Reductions or Interruptions

Venetoclax Plus Obinutuzumab in Patients With Untreated CLL

Epigenetic Diversity in CLL

Acalabrutinib Plus Obinutuzumab in Resistant CLL: 3-Year Follow-up

Final Results of COMPLEMENT 1 Trial: Ofatumumab and Chlorambucil in Untreated CLL

Potential Prognostic Markers in CLL: NOTCH1 Pathway Mutations

Atrial Fibrillation After Treatment With Ibrutinib in Patients With CLL

Treatment of Resistant CLL With Acalabrutinib

Acalabrutinib Granted Breakthrough Therapy Designation in CLL

CLL14 Trial: Paired With Obinutuzumab, Venetoclax Versus Chlorambucil in CLL

Acalabrutinib in Relapsed or Refractory CLL

CLL12 Trial: Ibrutinib Improves Outcomes in Early-Stage CLL

RESONATE2 Update on First-Line Ibrutinib in Older Patients With CLL/SLL

Secondary Cancers and BTK Inhibitors for CLL

Umbralisib in Kinase Inhibitor–Intolerant CLL

Method for Selecting Potential Ibrutinib-Based Combinations in CLL

CD19-Directed Immunotherapy for Relapsed or Refractory CLL

FDA Approves Rituximab Biosimilar for CLL

Obesity and Chemoimmunotherapy Outcomes for Patients With CLL

FDA Approves Venetoclax Plus Obinutuzumab as First-Line Treatment for CLL/SLL

Concurrent CLL, Kaposi Sarcoma, and Angiosarcoma

Does Ibrutinib Pose Cardiac or Pulmonary Risk in Patients With CLL?

Does Size of Extracellular Vesicles Impact Immunotherapy for CLL?

EHA24 Congress: ASCEND Trial of Acalabrutinib Monotherapy in Resistant CLL